Hologic, Inc. (HOLX)
- Previous Close
75.91 - Open
79.60 - Bid 76.48 x 600
- Ask 76.56 x 600
- Day's Range
75.58 - 79.75 - 52 Week Range
64.02 - 86.74 - Volume
1,962,265 - Avg. Volume
1,697,506 - Market Cap (intraday)
17.863B - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
39.45 - EPS (TTM)
1.94 - Earnings Date Jul 29, 2024 - Aug 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
86.21
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
www.hologic.com6,990
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: HOLX
Performance Overview: HOLX
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOLX
Valuation Measures
Market Cap
17.86B
Enterprise Value
18.25B
Trailing P/E
39.45
Forward P/E
18.90
PEG Ratio (5yr expected)
1.43
Price/Sales (ttm)
4.71
Price/Book (mrq)
3.69
Enterprise Value/Revenue
4.61
Enterprise Value/EBITDA
18.37
Financial Highlights
Profitability and Income Statement
Profit Margin
11.78%
Return on Assets (ttm)
6.26%
Return on Equity (ttm)
9.20%
Revenue (ttm)
3.96B
Net Income Avi to Common (ttm)
466.5M
Diluted EPS (ttm)
1.94
Balance Sheet and Cash Flow
Total Cash (mrq)
2.18B
Total Debt/Equity (mrq)
52.67%
Levered Free Cash Flow (ttm)
736.59M
Research Analysis: HOLX
Company Insights: HOLX
HOLX does not have Company Insights